FDA accepts VIAject NDA

FDA accepted for review an NDA from Biodel Inc. (NASDAQ:BIOD) for VIAject injectable recombinant human insulin to treat Type I and Type II diabetes. Biodel expects a PDUFA date of Oct. 30. Biodel subm...